The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal disease ...

Opus Genetics has dosed the first subject in its Phase I/II clinical trial of OPGx-Best1 gene therapy for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — Best practices for safe subretinal delivery of gene therapy were presented at the Retina ...

Please provide your email address to receive an email when new articles are posted on . Injection in the subretinal space, currently performed or investigated for several cell-based and gene therapy ...

The success of the surgery marks a key leap from "feasibility" to "practicality" in China's field of remote high-precision ophthalmic surgery and represents a major breakthrough in the country's ...

When the FDA approved Spark Therapeutics’ Luxturna in December 2017, gene therapy became a household concept. Chatter about gene therapy curing blindness became hot fodder at dinner tables and ...

Opus Genetics (IRD) announced that the first participant has been dosed in the Company’s OPGx-BEST1 Phase 1/2 clinical trial for Best disease. Best disease, or vitelliform macular dystrophy, is a rare ...